|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/22 | |||
| C07K 16/24 | |||
| A61P 35/00 |
| (11) | Number of the document | 3397281 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16826865.4 |
| Date of filing the European patent application | 2016-12-28 | |
| (97) | Date of publication of the European application | 2018-11-07 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/068847 |
| Date | 2016-12-28 |
| (87) | Number | WO 2017/117202 |
| Date | 2017-07-06 |
| (30) | Number | Date | Country code |
| 201562272116 P | 2015-12-29 | US |
| (72) |
TADDEI, Maria, US
CHEUNG, Jessica, US
GUTKA, Hiten, US
|
| (73) |
Outlook Therapeutics, Inc.,
7 Clarke Drive, Cranbury, NJ 08512,
US
|
| (54) | BUFFERED FORMULATIONS OF BEVACIZUMAB |
| BUFFERED FORMULATIONS OF BEVACIZUMAB |